Literature DB >> 19688969

Prognostic implication of immunohistochemical Runx2 expression in osteosarcoma.

Kyu Yeoun Won1, Hye-Rim Park, Yong-Koo Park.   

Abstract

AIMS AND
BACKGROUND: Osteosarcoma is the most common primary bone malignancy. Many genetic markers have proven prognostic value in osteosarcoma and studies are under way to determine their potential application as specific therapeutic targets. Runx2, Indian hedgehog (IHH), and Sox9 are proteins that play major roles in bone formation and tumorigenesis. We studied the protein expression of Runx2, IHH, and Sox9 in osteosarcoma and correlated their expression with clinicopathological variables. We also studied the prognostic value of the expression of these three genes in osteosarcoma. METHODS AND STUDY
DESIGN: We produced 48 formalin-fixed, paraffin-embedded tissue microarrays containing osteosarcoma tissue cores for immunohistochemical staining of Runx2, IHH and Sox9. We evaluated the expression of each gene by immunohistochemical staining and analyzed the relationship between expression and clinicopathological parameters.
RESULTS: High expression of Runx2 was significantly related to metastasis (P = 0.015). High expression of Runx2 indicated a trend toward a poor survival rate (P = 0.056). High expression of IHH and Sox9 were not related to any clinicopathological parameters.
CONCLUSIONS: High expression of Runx2 was significantly related to tumor metastasis in osteosarcoma. Our results suggest that overexpression of Runx2 might be a useful prognostic marker in osteosarcoma cases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19688969     DOI: 10.1177/030089160909500307

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  24 in total

1.  Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression.

Authors:  Kyle C Kurek; Sara Del Mare; Zaidoun Salah; Suhaib Abdeen; Hussain Sadiq; Suk-Hee Lee; Eugenio Gaudio; Nicola Zanesi; Kevin B Jones; Barry DeYoung; Gail Amir; Mark Gebhardt; Matthew Warman; Gary S Stein; Janet L Stein; Jane B Lian; Rami I Aqeilan
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  Expression of master regulatory genes controlling skeletal development in benign cartilage and bone forming tumors.

Authors:  Jane Y Dancer; Stephen P Henry; Jolanta Bondaruk; Sangkyou Lee; Alberto G Ayala; Benoit de Crombrugghe; Bogdan Czerniak
Journal:  Hum Pathol       Date:  2010-12       Impact factor: 3.466

3.  RUNX2 RNA interference inhibits the invasion of osteosarcoma.

Authors:  Heng Zeng; Xiaotao Xu
Journal:  Oncol Lett       Date:  2015-04-20       Impact factor: 2.967

4.  Targeted apc;twist double-mutant mice: a new model of spontaneous osteosarcoma that mimics the human disease.

Authors:  Natacha Entz-Werlé; Philippe Choquet; Agnès Neuville; Sabine Kuchler-Bopp; François Clauss; Jean-Marc Danse; Pauline Simo-Noumbissie; Eric Guérin; Marie-Pierre Gaub; Jean-Noel Freund; Nelly Boehm; André Constantinesco; Patrick Lutz; Dominique Guenot; Fabienne Perrin-Schmitt
Journal:  Transl Oncol       Date:  2010-12-01       Impact factor: 4.243

Review 5.  The RUNX family: developmental regulators in cancer.

Authors:  Yoshiaki Ito; Suk-Chul Bae; Linda Shyue Huey Chuang
Journal:  Nat Rev Cancer       Date:  2015-01-16       Impact factor: 60.716

6.  MiR-30a regulates the proliferation, migration, and invasion of human osteosarcoma by targeting Runx2.

Authors:  Ruyi Zhang; Shujuan Yan; Jing Wang; Fang Deng; Yangliu Guo; Ya Li; Mengtian Fan; Qilin Song; Hongxia Liu; Yaguang Weng; Qiong Shi
Journal:  Tumour Biol       Date:  2015-10-09

7.  The cancer-related transcription factor Runx2 modulates cell proliferation in human osteosarcoma cell lines.

Authors:  Claudia M J Lucero; Oscar A Vega; Mariana M Osorio; Julio C Tapia; Marcelo Antonelli; Gary S Stein; Andre J van Wijnen; Mario A Galindo
Journal:  J Cell Physiol       Date:  2013-04       Impact factor: 6.384

8.  RUNX2 (6p21.1) amplification in osteosarcoma.

Authors:  Sounak Gupta; Tatsuo Ito; Deepu Alex; Chad M Vanderbilt; Jason C Chang; Nasrin Islamdoust; Yanming Zhang; Khedoudja Nafa; John Healey; Marc Ladanyi; Meera R Hameed
Journal:  Hum Pathol       Date:  2019-10-25       Impact factor: 3.466

9.  Overexpression of runt-related transcription factor-2 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer.

Authors:  Weiping Li; Shujuan Xu; Shuang Lin; Wei Zhao
Journal:  J Biomed Biotechnol       Date:  2012-10-04

Review 10.  Molecular mechanisms underpinning sarcomas and implications for current and future therapy.

Authors:  Victoria Damerell; Michael S Pepper; Sharon Prince
Journal:  Signal Transduct Target Ther       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.